EA201990385A1 - HETEROCYCLIC COMPOUND AS JAK INHIBITOR AND ITS SALTS AND THERAPEUTIC USE - Google Patents

HETEROCYCLIC COMPOUND AS JAK INHIBITOR AND ITS SALTS AND THERAPEUTIC USE

Info

Publication number
EA201990385A1
EA201990385A1 EA201990385A EA201990385A EA201990385A1 EA 201990385 A1 EA201990385 A1 EA 201990385A1 EA 201990385 A EA201990385 A EA 201990385A EA 201990385 A EA201990385 A EA 201990385A EA 201990385 A1 EA201990385 A1 EA 201990385A1
Authority
EA
Eurasian Patent Office
Prior art keywords
salts
heterocyclic compound
therapeutic use
jak inhibitor
jak
Prior art date
Application number
EA201990385A
Other languages
Russian (ru)
Other versions
EA039344B1 (en
Inventor
Вэньянь Чжан
Original Assignee
Тяньцзинь Лонгбоджин Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тяньцзинь Лонгбоджин Фармасьютикал Ко., Лтд. filed Critical Тяньцзинь Лонгбоджин Фармасьютикал Ко., Лтд.
Priority claimed from PCT/CN2017/094253 external-priority patent/WO2018019222A1/en
Publication of EA201990385A1 publication Critical patent/EA201990385A1/en
Publication of EA039344B1 publication Critical patent/EA039344B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Описано гетероциклическое производное в качестве ингибитора JAK и его соли, где определения (II), (III) и R такие, как подробно описаны в спецификации. Кроме того, также описано лекарственное средство, содержащее соединение и его соли в качестве активного ингредиента, и их применение в производстве лекарственного средства для лечения связанных с JAK киназой заболеваний, таких как заболевания иммунной системы, ревматоидный артрит и опухоли.A heterocyclic derivative is described as an inhibitor of JAK and its salt, where definitions (II), (III) and R are as described in detail in the specification. In addition, a medicament containing the compound and its salts as an active ingredient is also described, and their use in the manufacture of a medicament for the treatment of JAK kinase-related diseases, such as diseases of the immune system, rheumatoid arthritis and tumors.

EA201990385A 2017-01-19 2017-07-25 Heterocyclic compound as jak inhibitor and salts and therapeutic use thereof EA039344B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710037675 2017-01-19
PCT/CN2017/094253 WO2018019222A1 (en) 2016-07-26 2017-07-25 Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof

Publications (2)

Publication Number Publication Date
EA201990385A1 true EA201990385A1 (en) 2019-07-31
EA039344B1 EA039344B1 (en) 2022-01-17

Family

ID=67399637

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201990385A EA039344B1 (en) 2017-01-19 2017-07-25 Heterocyclic compound as jak inhibitor and salts and therapeutic use thereof
EA201990386A EA039352B1 (en) 2017-01-19 2017-07-25 Compound as selective jak inhibitor and salts and therapeutic use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201990386A EA039352B1 (en) 2017-01-19 2017-07-25 Compound as selective jak inhibitor and salts and therapeutic use thereof

Country Status (1)

Country Link
EA (2) EA039344B1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG151327A1 (en) * 2005-09-30 2009-04-30 Vertex Pharmaceuticals Incopor Deazapurines useful as inhibitors of janus kinases
DK2455382T3 (en) * 2005-12-13 2017-01-02 Incyte Holdings Corp Heteroberl substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
CN101374839A (en) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 Azaindoles useful as inhibitors of janus kinases
EP1979353A2 (en) * 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
EA017218B1 (en) * 2008-03-11 2012-10-30 Инсайт Корпорейшн Azetidine and cyclobutane derivatives as jak inhibitors
JO3041B1 (en) * 2008-07-25 2016-09-05 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
CA2763900A1 (en) * 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
TWI462920B (en) * 2009-06-26 2014-12-01 葛萊伯格有限公司 Novel compound useful for the treatment of degenerative and inflammatory diseases

Also Published As

Publication number Publication date
EA039344B1 (en) 2022-01-17
EA201990386A1 (en) 2019-07-31
EA039352B1 (en) 2022-01-17

Similar Documents

Publication Publication Date Title
EA201992126A1 (en) JAK INHIBITORS CONTAINING 4-MEMBER HETEROCYCLIC AMIDE
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
CY1119771T1 (en) AMINOPYRIMININYLIUM COMPOUNDS AS SUSPENSIONS TOY JAK
EA201892207A1 (en) INDOLKARBOXAMIDE CONNECTIONS
CY1123627T1 (en) DIHYDROIMIDAZOPYZINONE DERIVATIVES USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER
EA201691151A1 (en) CONNECTIONS FOR THE TREATMENT OF PATIENTS WITH ROS1-MUTANT CANCER CELLS
EA201990643A1 (en) PHARMACEUTICAL COMPOUNDS
EA201792116A1 (en) JANUS KINASE INHIBITOR
EA201890594A1 (en) Aryl, Heteroaryl, and Heterocyclic Compounds for the Treatment of Disorders
EA201891203A1 (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
EA201790660A1 (en) KINAZ INHIBITOR
EA201792214A1 (en) COMPOUNDS OF SUBSTITUTE QUINAZOLINE
EA201690752A1 (en) INHIBITORS G12C KRAS
EA201891229A1 (en) EIF4A-INHIBITING COMPOUNDS AND RELATED METHODS
EA201991884A3 (en) G12C KRAS INHIBITORS
EA201592200A1 (en) DERIVATIVES OF SULFAMOILPYRROLAMIDE AND THEIR APPLICATION AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
EA201892075A1 (en) COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
EA201990833A1 (en) Pyridine compound
EA202090688A1 (en) BIS-AMIDE CONNECTIONS ACTIVATING SARCOMER AND VARIANTS OF THEIR APPLICATION
EA201791289A1 (en) INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS
EA201991700A1 (en) SELECTIVE INHIBITORS JAK1
EA201790870A1 (en) TRICYCLIC TROPICOMETRIC COMPOUNDS
EA202191478A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA201792057A1 (en) CONDENSED BICYCLIC HETEROYARIL DERIVATIVES WITH ACTIVITY OF PROHYLDROXYLASE INHIBITORS
EA201990678A1 (en) Heteroarylcarboxamide Compounds as Ripk2 Inhibitors

Legal Events

Date Code Title Description
TB4A Correction of composition of inventors in a published eurasian patent